



## Repurposing Existing Drugs - Systematic Approaches

05 Aug 2021 - 06 Aug 2021

### CONFERENCE PROGRAMME

#### Thursday, 5th August 2021

13:00	<b>Test Run and Web Checks</b>
13:30	<b>Pre-forum Workshop: Portfolio Enhancement &amp; Product Rationalization (Dr Avijit Kelkar, Co-Founder, AharavConsultants, UK)</b>
14:30	<b>Welcome Address and Introduction to Experts and Expert Forum</b> <b>Sanjay Bajaj</b> , CEO & MD , Glostem Private Limited , India
14:45	<b>Pharmacological &amp; Clinical Aspects in Drug Repurposing</b> <b>Amrish Srivastava</b> , Clinical Consultant , Evolve Life Research , India
15:15	<b>The Myths of Repurposing Drugs</b> <b>Ken V Phelps</b> , President & Founder , Camargo Pharmaceutical Services , USA
15:45	<b>Drug Repurposing in Oncology - From Candidate Selection to Clinical Investigation</b> <b>Pan Pantziarka</b> , Programme Director - Drug Repurposing , Anticancer Fund , United Kingdom
16:15	<b>Open Discussion/Rap Session: (Experts - Purushottam Dewang and Pratima Srivastava)</b>
16:35	<b>Regulatory Pathways for Repurposed Drugs and 505(B)2 Hurdles</b> <b>Asoke Mukherjee</b> , Former - Senior Expert Pharmacologist , FDA , USA
17:05	<b>Reverse Pharmacology and Systems Approaches for Chemical Biology, Drug Discovery and Development: Inspiration from the Wisdom of Mother Nature</b> <b>Mukund Chorghade</b> , President and Chief Scientific Officer , THINQ Pharma , USA
17:35	<b>End of First Day of meeting</b>

#### Friday, 6th August 2021

14:30	<b>Recap of Day 1 and Introduction to Day 2 Experts</b> <b>Sanjay Bajaj</b> , CEO & MD , Glostem Private Limited , India
14:40	<b>Repositioning of Existing Drugs through Novel Product Development Approaches</b> <b>Rakesh Bhasin</b> , Vice President - Gen-Form , Biocon Limited , India
15:10	<b>Open Discussion - Formulation Development Approaches (Lead Experts - Manish Grover and WantaneePhuapradit)</b>

15:29	<b>Drug Repurposing using In Silico and 3D Human Vascular Lung Models: A Case Example for Covid Antiviral Clinical Candidate Selection</b>
15:30	<b>Overview of Drug Repurposing for Covid Antiviral Clinical Candidate</b> <b>Subrahmanyam Vangala</b> , CEO & Co founder , ReaGene Biosciences Pvt Ltd, India (Keynote Speaker) , India
15:45	<b>In Silico Screening of 8000 FDA Drugs for SARS-Cov-2 Antiviral Activity</b> <b>Sreedhara R Voleti</b> , Founder-MD/CEO , INDRAS Pvt. Ltd , India
16:05	<b>3D Human Vascular Lung Model for Clinical Validation for Drug Repurposing as SARS-Cov-2 Antiviral Drugs</b> <b>Uday Saxena</b> , Co-Founder , Reagene Biosciences , India
16:25	<b>Q/A Session</b>
16:45	<b>Open Discussion - (Expert - Dr Purushottam Dewang)</b>
17:15	<b>Networking in Forum Lounge</b>
17:30	<b>Closing Remarks and End of the meeting</b>